Mitochondrial DNA Copy Number Tied to Tumor Growth and Chemotherapy Gene Activity

Mitochondria are tiny structures found inside almost every cell in the human body, and they carry out some of the most fundamental jobs in biology, above all the production of energy. What makes them unusual is that they hold a small set of their own DNA molecules, known as mitochondrial DNA or mtDNA, which are separate from the genetic material stored in the cell nucleus. That compact genome is essential for mitochondria to function properly. New research published in The FEBS Journal suggests that the amount of mtDNA a cancer cell carries may say something important about how aggressive that cancer is and how it responds to treatment.

The work, described in a study titled "Multi-cancer analysis reveals mtDNA copy number as a key determinant of mutational load and cancer progression," examined the relationship between the number of mtDNA copies present in cancer cells and a range of genetic and clinical features across multiple cancer types. Rather than focusing on a single tumor category, the analysis drew on data spanning different cancers, allowing the researchers to look for patterns that hold broadly rather than in one disease alone.

What the multi-cancer analysis measured

Mitochondrial DNA copy number refers to how many copies of the mitochondrial genome are present within a cell. Because mitochondria are the primary site of energy production, cells that need more energy often maintain larger populations of these organelles and, correspondingly, more copies of mtDNA. In cancer, that relationship becomes more complicated, since tumors frequently reprogram their metabolism to support rapid and uncontrolled division.

The researchers set out to determine whether variation in mtDNA copy number tracks with other measurable properties of tumors. According to the findings, it does. The analysis identified a correlation between mtDNA copy number and the extent of genetic mutations within cancer cells, hinting that mitochondrial DNA may play a role in shaping how severe a cancer becomes. The study's framing positions mtDNA copy number as a potentially important determinant of mutational load and disease progression across cancer types.

It is worth being precise about what a correlation of this kind means. The results describe a statistical association observed across tumor samples, not proof that mtDNA directly causes mutations or drives a cancer forward. Still, the consistency of the pattern across multiple cancers makes it a signal worth pursuing, because it raises the possibility that a relatively simple measurement could carry information about a tumor's underlying biology.

Mutation burden and cancer severity

Mutational load, or the total number of genetic alterations a tumor has accumulated, is a widely used indicator in oncology. Higher burdens can reflect genomic instability, and they influence how tumors behave and how they respond to certain therapies. A link between mtDNA copy number and mutational load therefore connects two biological features that researchers normally study separately.

The study's authors suggest that mitochondrial DNA may affect cancer severity, and the association they report provides a rationale for investigating that idea further. If mtDNA copy number reliably reflects mutation burden, it could eventually serve as an accessible proxy for a characteristic that is otherwise expensive and time-consuming to measure directly.

A signature of compensation

One of the more intriguing observations concerns what happens when mitochondrial function is impaired. The research found that an increase in mtDNA copy number carried a signature consistent with compensation for damaged or dysfunctional mitochondria in cancer cells. In other words, when mitochondrial performance falters, cells appear to respond by producing more copies of the mitochondrial genome, potentially as a way of shoring up energy production or other mitochondrial duties.

This compensatory pattern helps explain why mtDNA copy number is not simply a proxy for healthy, well-powered mitochondria. In a cancer context, a high copy number may instead signal that the cell is under stress and working to offset a defect, which could be one reason the measurement correlates with more advanced disease features.

Links to chemotherapy response genes

The analysis also connected variation in mtDNA copy number to differences in the expression of genes tied to chemotherapy response, as well as to genes involved in various other aspects of cancer biology. High mtDNA copy number in particular was associated with the expression of genes that support tumor growth and survival.

That finding has direct clinical resonance. Chemotherapy remains a cornerstone of cancer treatment, yet tumors vary widely in how they respond to it. If mtDNA levels correlate with the activity of genes that shape drug response, they could help explain part of that variability and, in time, inform how treatments are selected or combined.

The study does not claim that mtDNA copy number determines whether a patient will benefit from chemotherapy. Its contribution is to document associations that sharpen the case for deeper investigation into the mitochondrial side of cancer biology.

Why mitochondria are drawing more attention in oncology

For years, cancer research has concentrated heavily on mutations in nuclear DNA. Mitochondria have often been treated as supporting players, important for metabolism but peripheral to the genetic story of cancer. This study contributes to a growing shift in that perspective.

• Mitochondria supply the energy that proliferating tumor cells demand, making them central to cancer metabolism.
• Because mtDNA is present in many copies per cell, changes in copy number are a measurable and potentially practical signal.
• The association with mutational load suggests mitochondrial biology intersects with genomic instability.
• The link to chemotherapy-related gene expression points toward a possible role in treatment response.
• The compensatory signature indicates that mtDNA levels reflect cellular stress, not merely energy capacity.

What the researchers say comes next

Riddhiman Dhar, Ph.D., of the Indian Institute of Technology Kharagpur, the corresponding author of the work, framed the results as a starting point for further inquiry. According to Dhar, the findings reveal a close association between mtDNA copy number and both cancer progression and therapy response, and could pave the way for deeper investigations into the role of mitochondria in cancer that may ultimately enable new cancer management strategies.

That is a measured conclusion. Turning an association observed across tumor datasets into a tool that helps patients would require additional research, including studies that track how mtDNA copy number changes over the course of disease and how it relates to outcomes in real clinical settings. The value of the current paper lies in establishing a broad, cross-cancer pattern and giving other researchers a clear direction to follow.

Key takeaways

• Mitochondria carry their own DNA, known as mtDNA, which is essential for their function.
• Research in The FEBS Journal found a correlation between mtDNA copy number and the extent of mutations in cancer cells.
• Rising mtDNA copy number showed a signature consistent with compensation for impaired mitochondrial function.
• Variation in copy number was associated with the expression of genes linked to chemotherapy response.
• High mtDNA copy number was tied to the activity of genes that support tumor growth and survival.
• The authors say the findings could open the door to new investigations and, eventually, new approaches to managing cancer.

This article is based on reporting by Medical Xpress. Read the original article.